EU Pharma legislation: Ηow it could impact access and innovation

Panel discussion on EU Pharma legislation; Ηow it could impact access and innovation at 1st SfEE Summit

√ Olga Solomon, Head of Unit Medicines: Policy, Authorisation and Monitoring, DG SANTE- European Commission, Belgium
√ Stelios Kympouropoulos Member of the European Parliament, European People’s Party Group, Coordinator - Environment, Public Health and Food Safety
√ Aris Angelis, Secretary General for Strategic Planning, Ministry of Health, Hellenic Republic
√ Michael Himonas, General Manager, Hellenic Association of Pharmaceutical Companies (SFEE), Greece
√ Wojciech Nowak, Group Senior Director Global Governmental & Public Affairs, Novartis; Chairman of the Healthcare Council, EuropaBio, Switzerland √ Dimitrios Athanasiou, Rare Disease Greece President, BoD World Duchenne Organization, PCWP Member European Medicines Agency

√ Moderator: Vasiliki Angouridi, Health Editor, News4Health.gr / Euractiv.com


The Hellenic Association of Pharmaceutical Companies (SFEE) organized the 1st SfEE Summit, which took place on June 18th, 2024, at the Megaron International Conference Center in Athens.

In a dynamically evolving environment, the challenges facing the Greek healthcare and pharma sector make the redefinition of the role and value of our sector to the healthcare system, society, and the economy imperative.

The 1st SfEE Summit, under the main theme “Redefining Value," focused on the value of the pharmaceutical industry to the Greek economy, the value and role of pharmaceutical innovation, the latest trends in the healthcare and pharma environment, as well as the challenges and opportunities of the Greek pharma sector.

https://sfeesummit.gr/